U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H26N4O5S
Molecular Weight 482.552
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMENAMEVIR

SMILES

CC1=CC=CC(C)=C1N(CC(=O)NC2=CC=C(C=C2)C3=NOC=N3)C(=O)C4CCS(=O)(=O)CC4

InChI

InChIKey=MNHNIVNAFBSLLX-UHFFFAOYSA-N
InChI=1S/C24H26N4O5S/c1-16-4-3-5-17(2)22(16)28(24(30)19-10-12-34(31,32)13-11-19)14-21(29)26-20-8-6-18(7-9-20)23-25-15-33-27-23/h3-9,15,19H,10-14H2,1-2H3,(H,26,29)

HIDE SMILES / InChI

Description

Amenamevir is an antiviral agent discovered by Astellas Pharma Inc. and is considered to exert anantiviral effect by inhibiting the activity of the helicase-primase complex, which is involved in DNA replication of herpes virus. It is a helicase-primase inhibitor against herpes simplex virus 1 (HSV-1), HSV-2, and varicella zoster virus. Amenamevir inhibited the in vitro replication of HSV-1 with a mean 50% effective concentration (EC(50)) of 14 ng/ml. Amenamevir was approved in Japan for the treatment of Herpes zoster.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

PubMed

Sample Use Guides

In Vivo Use Guide
Herpes zoster: The usual adult dosage is 400 mg of amenamevir administered orally once daily after a meal
Route of Administration: Oral
In Vitro Use Guide
Amenamevir inhibited the DNA-dependent ATPase activity of the HSV-1 helicase-primase complex within the concentration range from 0.0001 to 3 umol/L in a concentration-dependent manner, and the 50% inhibitory concentration (IC50) was 0.078 umol/L.